NewsfeedFollowed Companies

Principia BioPharma's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Principia Biopharma is a developer of small molecule drugs for the treatment of cancer and inflammatory diseases.

Princip... Read more

Based on data from Principia BioPharma's latest SEC filings

Annual Revenue

Based on data from Principia BioPharma's latest SEC filings

Employees

Martin Babler's photo - CEO of Principia BioPharma

CEO

Martin Babler

CEO Approval Rating

75/100

OVERVIEW

Founded:

2008

Headquarters:

South San FranciscoCalifornia

Status:

PublicIndependent Company of NASDAQPRNB

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Galena Biopharma a competitor of Principia BioPharma?

I don't know

Trending News for Principia BioPharma and Principia BioPharma's Competitors

December 13, 2019

MarketScreener

Exelixis : Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

(marketscreener.com) Exelixis, Inc. (Nasdaq: EXEL) today announced positive results from IMspire150, ... See more »

December 13, 2019

Pharmaceutical Manufacturing

Lilly, Boehringer's Jardiance has heart failure trial setback

Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in ad... See more »

December 13, 2019

Seeking Alpha

European advisory group backs Novartis' brolucizumab for wet AMD

See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Innovimmune Biotherapeutics is seen as one of Principia BioPharma's top competitors. Innovimmune Biotherapeutics's headquarters is in New York, New York, and was founded in 2010. Like Principia BioPharma, Innovimmune Biotherapeutics also works within the Biotechnology industry. Innovimmune Biotherapeutics generates 3.26% of Principia BioPharma's revenue.

ASLAN Pharmaceuticals is one of Principia BioPharma's top rivals. ASLAN Pharmaceuticals was founded in 2010, and its headquarters is in Singapore, Central Singapore. Like Principia BioPharma, ASLAN Pharmaceuticals also works within the Biotechnology field. ASLAN Pharmaceuticals has 13 fewer employees than Principia BioPharma.

Akari is Principia BioPharma's #3 rival. Akari is a Public company that was founded in 2005 in London, England. Akari competes in the Pharmaceuticals industry. Compared to Principia BioPharma, Akari has 56 fewer employees.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Martin Babler

CEO

- -
69
$246.2M
$61.3M
1

Anderson Gaweco

President & CEO

70/100
3
- -
$2M
2

Carl Firth

Founder & CEO

83/100
56
$145M
$ < 1M
3

Clive Richardson

CEO

88/100
13
$90M
$ < 1M
4

Stephen F. Ghiglieri

Interim-CEO

70/100
6
$33.1M
$9.7M
5

Patrick J. Mahaffy

President & CEO

80/100
278
$763.3M
$134.1M
6

Sean A. McCarthy

Chairman & CEO

90/100
78
$184.4M
$60.7M
7

Alexander Hardy

CEO

74/100
14,717
$100M
$18.3B
8

Scott Garland

President & CEO

77/100
163
$772M
$102.7M
9

CEO

- -
50,370
- -
$20B
10

Lee Babiss

CEO

87/100
3
$54M
$ < 1M
The top 10 competitors in Principia BioPharma's competitive set are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals, Akari, Galena Biopharma, Clovis Oncology, CytomX, Genentech, Portola, Boehringer Ingelheim and Gotham Therapeutics. Together they have raised over 2.1B between their estimated 66.1K employees. Principia BioPharma has 69 employees and is ranked 6th among it's top 10 competitors. The top 10 competitors average 5,977.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$61.3M

Principia BioPharma's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 3.5B. Over the last four quarters, Principia BioPharma's revenue has grown by 61.6%. Specifically, in Q2 2019's revenue was $30M; in Q1 2019, it was $5.2M; in Q4 2018, it was $26.1M; in Q3 2018, Principia BioPharma's revenue was $18.6M.

Acquisitions

No recent acquisitions found related to Principia BioPharma

Principia BioPharma Funding History

Since Principia BioPharma was founded in 2008, it has participated in 6 rounds of funding. In total Principia BioPharma has raised $246.2M. Principia BioPharma's last funding round was on Aug 2018 for a total of $50.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Aug 2018
$50M
-
Equity
Jul 2015
$15.3M
Series B
Apr 2014
$50M
Series A
Oct 2012
$12.5M
Equity
Feb 2011
$12.1M

Total Funding: $246.2M

Since Principia BioPharma was founded in 2008, it has participated in 6 rounds of funding. In total Principia BioPharma has raised $246.2M. Principia BioPharma's last funding round was on Aug 2018 for a total of $50.0M

Investments

No recent investments found related to Principia BioPharma

Principia BioPharma News

October 28, 2019Insider Monkey

Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?

See more »
October 16, 2019Seeking Alpha

Principia prices stock offering; shares down 6% after hours

See more »
October 15, 2019Seeking Alpha

Principia Bio up 3% on positive PRN1008 data

See more »
October 10, 2019Seeking Alpha

Principia's lead candidate shows positive action in second stage of pemphigus study

See more »
August 27, 2019Benzinga

Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB)... See more »
June 2, 2019Zolmax News

$8.00 Million in Sales Expected for Principia Biopharma Inc (PRNB) This Quarter

Wall Street analysts forecast that Principia Biopharma Inc (NASDAQ:PRNB) will post $8.00 million in s... See more »
May 8, 2019Finance Daily

Principia Biopharma (NASDAQ:PRNB) and Its Rivals

Principia Biopharma (NASDAQ: PRNB) is one of 553 publicly-traded companies in the "Pharmaceutical pre... See more »

Principia BioPharma Press Releases

July 30, 2019GlobeNewswire

Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP

SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB... See more »
May 20, 2019GlobeNewswire

Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer

-- FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in m... See more »
May 14, 2019GlobeNewswire

Principia Biopharma Announces First Patient Dosed in Sanofi's Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 9, 2019GlobalNewswire

Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 7, 2019GlobeNewswire

Principia Biopharma Reports First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
May 7, 2019StreetInsider

Principia Biopharma Reports First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
March 20, 2019GlobeNewswire

Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRN... See more »

Principia BioPharma Videos

Headquarters

400 East Jamie Court Suite 302

South San Francisco, California94080

650-416-7700

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Principia Biopharma is a developer of small molecule drugs for the treatment of cancer and inflammatory diseases. Principia BioPharma was founded in 2008. Principia BioPharma's headquarters is located in South San Francisco, California, USA 94080. It ...

CEO

Principia BioPharma's CEO, Martin Babler, currently has an approval rating of 75%. Principia BioPharma's primary competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals & Akari.

Website

principiabio.com

Frequently Asked Questions about Principia BioPharma

  1. When was Principia BioPharma founded?

    Principia BioPharma was founded in 2008

  2. Who is Principia BioPharma's CEO?

    Principia BioPharma's CEO is Martin Babler

  3. How much revenue does Principia BioPharma generate?

    Principia BioPharma generates $61.3M in revenue

  4. How much funding does Principia BioPharma have?

    Principia BioPharma has historically raised $246.2M in funding

  1. Where is Principia BioPharma's headquarters?

    Principia BioPharma's headquarters is in South San Francisco California, USA

  2. How many employees does Principia BioPharma have?

    Principia BioPharma has 69 employees

  3. What sector does Principia BioPharma operate in?

    Principia BioPharma is in Biotechnology

  4. Who are Principia BioPharma's competitors?

    Principia BioPharma's top competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals, Akari
Stay up-to-date with the latest news on Principia BioPharma